Minimal Residual Disease Assessment in CLL/SLL: Is It Ready for Routine Clinical Practice?

Presenter: Jennifer A. Woyach

Minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL) is defined as <1 CLL cell per 10,000 leukocytes (0.01%; <10−4). Flow cytometry and next-generation sequencing have demonstrated high sensitivity in MRD detection. MRD assessment may help to determine prognosis after fixed-duration regimens; this has been established in the contexts of chemoimmunotherapy and venetoclax/antibody combinations. In the short term, MRD status does not seem to inform prognosis in patients treated with a BTK inhibitor plus venetoclax-based regimens; however, long-term data will be needed to determine whether it is beneficial in this population. Numerous trials have demonstrated that MRD may be used to guide therapy. It is unclear whether using an MRD-guided treatment strategy is better than using fixed-duration therapy; ongoing and future studies are warranted.

Disclosures: Dr. Woyach has disclosed receiving consulting fees from AbbVie, Inc., AstraZeneca Pharmaceuticals LP, BeiGene, Eli Lilly and Company, Janssen Pharmaceutica Products, LP, and Pharmacyclics; receiving grant/research support from AbbVie, Inc., Janssen Pharmaceutica Products, LP, Karyopharm Therapeutics, MorphoSys AG, Pharmacyclics, and Schrodinger; and serving as a scientific advisor for Newave.

Correspondence: Jennifer A. Woyach, MD, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, 410 West 10th Avenue, Columbus, OH 43210. Email: Jennifer.Woyach@osumc.edu
  • 1.

    Rawstron AC, Fazi C, Agathangelidis A, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia 2016;30:929936.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Rawstron AC, Kreuzer KA, Soosapilla A, et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) harmonisation project. Cytometry B Clin Cytom 2018;94B:121128.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Raponi S, Starza ID, De Propris MS, et al. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients: a comparative analysis of flow cytometry and ASO IgH RQ-PCR. Br J Haematol 2014;166:360368.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Thompson PA. MRD negativity as a surrogate for PFS in CLL? Blood 2018;131:943944.

  • 5.

    Dimier N, Delmar P, Ward C, et al. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood 2018;131:955962.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol 2019;37:269277.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Kater AP, Wu JQ, Kipps T, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol 2020;38:40424054.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2020;21:11881200.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Rogers KA, Huang Y, Ruppert AS, et al. Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naive and relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2020;38:36263637.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Jain N, Keating M, Thompson P, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia a nonrandomized phase 2 trial. JAMA Oncol 2021;7:12131219.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Allan JN, Wierda WG, Siddiqi T, et al. Primary analysis of the fixed-duration cohort from the phase 2 CAPTIVATE study of first-line ibrutinib + venetoclax for chronic lymphocytic leukemia/small lymphocytic lymphoma [abstract]. Presented at the European Hematology Association (EHA) Congress 2021; June 9–17, 2021. Abstract S147.

    • Search Google Scholar
    • Export Citation
  • 12.

    Kater A, Owen C, Moreno C, et al. Fixed-duration ibrutinib and venetoclax versus chlorambucil plus obinutuzumab for first-line chronic lymphocytic leukemia: primary analysis of the phase 3 GLOW study [abstract]. Presented at the European Hematology Association (EHA) Congress 2021; June 9–17, 2021. Abstract LB1902.

    • Search Google Scholar
    • Export Citation
  • 13.

    Wierda WG, Tam CS, Allan JN, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma: 1-year disease-free survival results from the MRD cohort of the phase 2 CAPTIVATE study [abstract]. Blood 2020;136:1617.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Siddiqi T, Tam CS, Allan JN, et al. First-line ibrutinib + venetoclax for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: efficacy and safety results from captivate MRD cohort [abstract]. Presented at the European Hematology Association (EHA) Congress 2020; June 11–21, 2020. Abstract S158.

    • Search Google Scholar
    • Export Citation
  • 15.

    Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol 2019;37:27222729.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Hillmen P, Boucher RH, Webster N, et al. Continued long term responses to ibrutinib + venetoclax treatment for relapsed/refractory CLL in the blood cancer UK TAP Clarity Trial [abstract]. Blood 2020;136:1718.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Soumerai JD, Mato AR, Carter J, et al. MRD-driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated chronic lymphocytic leukemia [abstract]. Presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition; December 5–8, 2020. Abstract 1307.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 301 301 301
PDF Downloads 157 157 157
EPUB Downloads 0 0 0